Cargando…
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
Hepatic inflammation drives hepatic stellate cells (HSC), resulting in liver fibrosis. The Farnesoid-X receptor (FXR) antagonizes inflammation through NF-κB inhibition. We investigated preventive and therapeutic effects of FXR agonist obeticholic acid (OCA) on hepatic inflammation and fibrosis in to...
Autores principales: | Verbeke, Len, Mannaerts, Inge, Schierwagen, Robert, Govaere, Olivier, Klein, Sabine, Vander Elst, Ingrid, Windmolders, Petra, Farre, Ricard, Wenes, Mathias, Mazzone, Massimiliano, Nevens, Frederik, van Grunsven, Leo A., Trebicka, Jonel, Laleman, Wim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025787/ https://www.ncbi.nlm.nih.gov/pubmed/27634375 http://dx.doi.org/10.1038/srep33453 |
Ejemplares similares
-
Bench-to-beside review: Acute-on-chronic liver failure - linking the gut, liver and systemic circulation
por: Verbeke, Len, et al.
Publicado: (2011) -
Managing portal hypertension in patients with liver cirrhosis
por: Sauerbruch, Tilman, et al.
Publicado: (2018) -
Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
por: Lin, Chuangzhen, et al.
Publicado: (2022) -
Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023) -
The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)